Compounds and uses thereof

• US 20040248972A1
• Filed: 05/17/2004
• Published: 12/09/2004
• Est. Priority Date: 05/16/2003
• Status: Abandoned Application

• Current Assignee: Ambit Biosciences Corporation (Daiichi Sankyo Company Limited)
• Original Assignee: Ambit Biosciences Corporation (Daiichi Sankyo Company Limited)
• Inventors: Patel, Hitesh K., Lockhart, David J., Milanov, Zdravko V., Mehta, Shamal Anil
• Application Number:
  US10/848,515
• Publication Number:
  US 20040248972A1
• Time in Patent Office: Days
• US Class Current: 514/460
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/225 Polycarboxylic acids
• CPC Class Codes: A61K 31/366 having six-membered rings, e.g. delta-lactones
• CPC Class Codes: A61K 31/381 having five-membered rings
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings

Abstract

The invention provides derivatives of statin compounds, preferably with reduced, or unappreciable, inhibitory activity against HMG-CoA reductase as well as compositions comprising such compounds. The invention also provides methods of using the compounds and/or compositions in the treatment of a variety of diseases and unwanted conditions in subjects. Kits comprising the non-statin compounds of the invention are also provided.

Claims

1. A statin composition comprising a non-statin compound wherein said non-statin compound is a statin compound lacking a HMG CoA reductase moiety, wherein said HMG CoA reductase moiety interacts with an HMG CoA reductase enzyme.

2. The non-statin compound of claim 1 wherein said HMG CoA reductase moiety is a heptanoic carboxylic acid or a lactone ring.

3. The non-statin compound of claim 1 wherein said HMG CoA reductase moiety is at least one of the following groups

4. A pharmaceutical composition comprising the composition of claim 1 and a pharmaceutically acceptable excipient.

5. A method of treating a disease comprising administering to a subject in need thereof an effective amount of the composition of claim 1.

6. The method of claim 5 wherein said disease is a cerebrovascular accident.

7. The method of claim 6 wherein said cerebrovascular accident is stroke.

8. The method of claim 6 wherein said subject has previously suffered a stroke.

9. The method of claim 5 wherein said disease is a cardiovascular disease.

10. The method of claim 9 wherein said treatment of cardiovascular disease decreases the frequency and/or the severity or damage of myocardial infarction in said subject.

11. The method of claim 5 wherein said disease is inflammation or multiple sclerosis.

12. The method of claim 5 wherein said disease is an acute coronary syndrome.

13. The method of claim 12 wherein said syndrome is selected from myocardial infarction, non-Q-wave myocardial infarction and unstable angina.

14. A method of stimulating blood vessel growth, bone growth, and/or an immune system comprising administering to a subject in need thereof an effective amount of a compound of claim 1.

15. The method of claim 5 wherein said disease is a PDE6-related condition.

16. The method of claim 15 wherein said PDE6-related condition is at least one of a condition selected from neurodegenerative condition, visual impairment disorder, proliferative. disorders, and cardiovascular-related condition.

17. The method of claim 16 wherein said neurodegenerative condition is at least one condition selected from ischemic stroke, basal ganglia, Parkinson'"'"'s disease, epilepsy, brain or spinal cord ischemia or trauma, Alzheimer'"'"'s disease, dementia, diabetic peripheral neuropathy, multiple sclerosis, amyotrophic lateral sclerosis, traumatic brain injury, spinal cord injury, and Huntington'"'"'s disease.

18. The method of claim 16 wherein said visual impairment disorder is at least one discorder selected from macular degeneration, amblyopia, Blepharitis, Bietti'"'"'s Crystalline Dystrophy, comeal disease, diabetic eye disease, glaucoma, histoplasmosis, and retinitis pigmentosa.

19. The method of claim 16 wherein said cardiovascular-related condition is at least one condition selected from atherosclerosis, myocardial infarction, congestive heart failure, ischemic-reperfusion injury, and vascular inflammatory conditions.

20. The method of claim 16 wherein said proliferative disorder is at least one disorder selected from leukemia, melanoma, Non-Hodgkins Lymphoma, bladder cancer, breast cancer, colon cancer, endometrial cancer, head and neck cancer, lung cancer, ovarian cancer, prostate cancerand rectal cancer.

21. A method of treating a PDE6-realated condition comprising administering to a subject in need thereof an effective amount of a statin compound.

22. The method of claim 21 wherein said statin compound is at least one of a statin selected from the following lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, rosuvastatin, pitavastatin, dalvastatin, glenvastatin, bervastatin, cerivastatin, and carvastatin.